Tailor-made Antibodies
and Tools for Life Science
Home|||||Technical Support

GAD1 / GAD67 antibody - 198 009

GAD1 and 2 are involved in the synthesis of GABA, the major inhibitory neurotransmitter
Chicken monoclonal recombinant IgY
Cat. No.: 198 009
Amount: 50 µg
Price: $415.00
Cat. No. 198 009 50 µg purified recombinant IgY, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 50 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 1000 up to 1 : 2000 (AP-staining) gallery  
IP: yes
ICC: 1 : 500 up to 1 : 1000 gallery  
IHC: 1 : 5000 (see remarks) gallery  
IHC-P: 1 : 2000 up to 1 : 4000 gallery  
Clone Ch126G12
Subtype IgY (λ light chain)
Immunogen Recombinant protein corresponding to residues near the amino-terminus of mouse GAD1. (UniProt Id: P48318)
Reactivity Reacts with: mouse (P48318), rat (P18088).
Other species not tested yet.
Remarks

This antibody is a chimeric antibody based on the monoclonal mouse antibody clone 126G12. The constant regions of the heavy and light chains have been replaced by chicken specific sequences. Therefore, the antibody can be used with standard anti-chicken secondary reagents. The antibody has been expressed in mammalian cells.
IHC: Antigen retrieval (10mM citrate, pH 6.0, overnight at 60°C) is recommended

Data sheet 198_009.pdf
Cat. No.: 198 009
Amount: 50 µg
Price: $415.00
Background

The glutamic acid decarboxylases GAD 1, also referred to as GAD 67, and GAD 2 / GAD 65 synthesize γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. The hydrophilic GAD 1 can heterodimerize with the membrane achored GAD 2 and part of GAD 1 is targeted to inhibitory nerve terminals by this mechanisms. Although both proteins exhibit significant differences in their N-terminus they share high homology in the rest of the molecule.
GADs are widely used markers for the GABAergic system. In type 1 diabetes GAD 1 has been identified as a major autoantigen.